Joel Schneider
Chief Executive Officer at Carbon Biosciences, Inc.
Profile
Joel Schneider is currently the President & Chief Executive Officer at Carbon Biosciences, Inc. Prior to his current position, he served as the Chief Operating Officer at Solid Biosciences, Inc. from 2021 to 2022.
Dr. Schneider completed his undergraduate degree at Brandeis University in 2006 and obtained his doctorate from Rutgers State University of New Jersey in 2012.
Joel Schneider active positions
| Companies | Position | Start |
|---|---|---|
Carbon Biosciences, Inc.
 Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Chief Executive Officer | - |
Former positions of Joel Schneider
| Companies | Position | End |
|---|---|---|
| SOLID BIOSCIENCES INC. | Chief Tech/Sci/R&D Officer | 2021-03-01 |
Training of Joel Schneider
| Brandeis University | Undergraduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SOLID BIOSCIENCES INC. | Health Technology |
| Private companies | 1 |
|---|---|
Carbon Biosciences, Inc.
Carbon Biosciences, Inc. Medical/Nursing ServicesHealth Services Carbon Biosciences, Inc. is a biotech company that is based in Boston, MA. The company is focused on expanding the therapeutic potential of gene therapy through its proprietary platform which leverages novel parvoviruses that have been pressure tested by nature to target specific tissues and carry a larger cargo with minimal neutralizing immunity and the potential to re-dose. The company is working to expand the gene therapy toolbox for the treatment of the world's most devastating and difficult to treat diseases. Carbon was founded by Longwood Fund and gene therapy pioneers, John F. Engelhardt, Ph.D., and Robert M. Kotin, Ph.D. | Health Services |
- Stock Market
- Insiders
- Joel Schneider
